Management of osteoporosis in rheumatoid arthritis patients

Bibliography

• McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011;365(23):2205-19
   PubMed Web of Science ®Google Scholar
• Vis M, Havaardsholm EA, Haugeberg G, et al. Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 2006;65(11):1495-9
   PubMed Web of Science ®Google Scholar
• van Staa TP, Geusens P, Bijlsma JW, et al. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 2006;54(10):3104-12
   PubMed Web of Science ®Google Scholar
• Vis M, Guler-Yuksel M, Lems WF. Can bone loss in rheumatoid arthritis be prevented? Osteoporos Int 2013;24(10):2541-53
   PubMed Web of Science ®Google Scholar
• Miao CG, Yang YY, He X, et al. Wnt signaling pathway in rheumatoid arthritis, with special emphasis on the different roles in synovial inflammation and bone remodeling. Cell Signal 2013;25(10):2069-78
   PubMed Web of Science ®Google Scholar
• Dawson-Hughes B, Looker AC, Tosteson AN, et al. The potential impact of the National Osteoporosis Foundation guidance on treatment eligibility in the USA: an update in NHANES 2005-2008. Osteoporos Int 2012;23(3):811-20
   PubMed Web of Science ®Google Scholar
• Netelenbos JC, Geusens PP, Ypma G, Buijs SJ. Adherence and profile of non-persistence in patients treated for osteoporosis--a large-scale, long-term retrospective study in The Netherlands. Osteoporos Int 2011;22(5):1537-46
   PubMed Web of Science ®Google Scholar
• Dutch guideline on osteoporosis. Third revision. Institute for quality of health CBO; Utrecht: 2011. 2011
   Google Scholar
• Bultink IE, Vis M, van der Horst-Bruinsma IE, Lems WF. Inflammatory rheumatic disorders and bone. Curr Rheumatol Rep 2012;14(3):224-30
   PubMed Web of Science ®Google Scholar
• Haugeberg G, Uhlig T, Falch JA, et al. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register. Arthritis Rheum 2000;43(3):522-30
   PubMed Web of Science ®Google Scholar
• Siris ES, Chen YT, Abbott TA, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 2004;164(10):1108-12
   PubMedGoogle Scholar
• Genant HK, Engelke K, Prevrhal S. Advanced CT bone imaging in osteoporosis. Rheumatology (Oxford) 2008;47(Suppl 4):iv9-16
   PubMed Web of Science ®Google Scholar
• Bultink IE, Lems WF. Performance of vertebral fracture assessment in addition to dual energy X-ray absorptiometry in patients with rheumatoid arthritis. Rheumatology (Oxford) 2014;53(5):775-6
   PubMed Web of Science ®Google Scholar
• Mohammad A, Lohan D, Bergin D, et al. The prevalence of vertebral fracture on vertebral fracture assessment imaging in a large cohort of patients with rheumatoid arthritis. Rheumatology (Oxford) 2014;53(5):821-7
   PubMed Web of Science ®Google Scholar
• Black DM, Arden NK, Palermo L, et al. Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group. J Bone Miner Res 1999;14(5):821-8
   PubMed Web of Science ®Google Scholar
• Schousboe JT, Debold CR. Reliability and accuracy of vertebral fracture assessment with densitometry compared to radiography in clinical practice. Osteoporos Int 2006;17(2):281-9
   PubMed Web of Science ®Google Scholar
• Pasco JA, Seeman E, Henry MJ, et al. The population burden of fractures originates in women with osteopenia, not osteoporosis. Osteoporos Int 2006;17(9):1404-9
   PubMed Web of Science ®Google Scholar
• Lems WF, Raterman HG, van den Bergh JP, et al. Osteopenia: a diagnostic and therapeutic challenge. Curr Osteoporos Rep 2011;9(3):167-72
   PubMedGoogle Scholar
• Genant HK, Jergas M, Palermo L, et al. Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis The Study of Osteoporotic Fractures Research Group. J Bone Miner Res 1996;11(7):984-96
   PubMed Web of Science ®Google Scholar
• Sambrook PN, Abeyasekera G, Ansell BM, et al. Calcium absorption in rheumatoid arthritis. Ann Rheum Dis 1985;44(9):585-8
   PubMed Web of Science ®Google Scholar
• Klein RG, Arnaud SB, Gallagher JC, et al. Intestinal calcium absorption in exogenous hypercortisonism. Role of 25-hydroxyvitamin D and corticosteroid dose. J Clin Invest 1977;60(1):253-9
   PubMed Web of Science ®Google Scholar
• Bijlsma JW, Duursma SA, Bosch R, et al. Acute changes in calcium and bone metabolism during methylprednisolone pulse therapy in rheumatoid arthritis. Br J Rheumatol 1988;27(3):215-19
   PubMedGoogle Scholar
• Brance ML, Brun LR, Lioi S, et al. Vitamin D levels and bone mass in rheumatoid arthritis. Rheumatol Int 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Als OS, Riis B, Christiansen C. Serum concentration of vitamin D metabolites in rheumatoid arthritis. Clin Rheumatol 1987;6(2):238-43
   PubMed Web of Science ®Google Scholar
• Reid IR, Bolland MJ, Grey A. Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis. Lancet 2014;383(9912):146-55
   PubMed Web of Science ®Google Scholar
• Avenell A, Mak Jenson CS, O’Connell D. Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men. Cochrane Database Syst Rev 2014. Available from: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000227.pub4/abstract. [Last accessed April 2014]
   Google Scholar
• Van Hemelrijck M, Michaelsson K, Linseisen J, Rohrmann S. Calcium intake and serum concentration in relation to risk of cardiovascular death in NHANES III. PLoS One 2013;8(4):e61037
   PubMed Web of Science ®Google Scholar
• Walsh JP, Divitini ML, Knuiman MW. Plasma calcium as a predictor of cardiovascular disease in a community-based cohort. Clin Endocrinol (Oxf) 2013;78(6):852-7
   PubMed Web of Science ®Google Scholar
• Choy E, Ganeshalingam K, Semb AG, et al. Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology (Oxford) 2014;53(12):2143-54
   PubMed Web of Science ®Google Scholar
• Gallagher JC, Sai A, Templin TII, Smith L. Dose response to vitamin D supplementation in postmenopausal women: a randomized trial. Ann Intern Med 2012;156(6):425-37
   PubMed Web of Science ®Google Scholar
• Evstigneyeva L, Kozhemyakina E, Lesnyak O, et al. Effect of excercise for patient with osteoporotic vertebral fractures. Ann Rheum Dis 2013;72(Supp l3):137
   Google Scholar
• de Jong Z, Munneke M, Lems WF, et al. Slowing of bone loss in patients with rheumatoid arthritis by long-term high-intensity exercise: results of a randomized, controlled trial. Arthritis Rheum 2004;50(4):1066-76
   PubMed Web of Science ®Google Scholar
• Kleyer A, Finzel S, Rech J, et al. Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies. Ann Rheum Dis 2014;73(5):854-60
   PubMed Web of Science ®Google Scholar
• Harre U, Georgess D, Bang H, et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest 2012;122(5):1791-802
   PubMed Web of Science ®Google Scholar
• Minaur NJ, Kounali D, Vedi S, et al. Methotrexate in the treatment of rheumatoid arthritis. II. In vivo effects on bone mineral density. Rheumatology (Oxford) 2002;41(7):741-9
   PubMed Web of Science ®Google Scholar
• di Munno O, Mazzantini M, Sinigaglia L, et al. Effect of low dose methotrexate on bone density in women with rheumatoid arthritis: results from a multicenter cross-sectional study. J Rheumatol 2004;31(7):1305-9
   PubMed Web of Science ®Google Scholar
• O’Dell JR, Mikuls TR, Taylor TH, et al. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med 2013;369(4):307-18
   PubMed Web of Science ®Google Scholar
• Kobayashi Y, Ueyama S, Arai Y, et al. The active metabolite of leflunomide, A771726, inhibits both the generation of and the bone-resorbing activity of osteoclasts by acting directly on cells of the osteoclast lineage. J Bone Miner Metab 2004;22(4):318-28
   PubMed Web of Science ®Google Scholar
• Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69(4):631-7
   PubMed Web of Science ®Google Scholar
• Dirven L, Guler-Yuksel M, de Beus WM, et al. Changes in hand bone mineral density and the association with the level of disease activity in patients with rheumatoid arthritis: bone mineral density measurements in a multicenter randomized clinical trial. Arthritis Care Res (Hoboken) 2011;63(12):1691-9
   PubMed Web of Science ®Google Scholar
• van der Goes MC, Jacobs JW, Jurgens MS, et al. Are changes in bone mineral density different between groups of early rheumatoid arthritis patients treated according to a tight control strategy with or without prednisone if osteoporosis prophylaxis is applied? Osteoporos Int 2013;24(4):1429-36
   PubMed Web of Science ®Google Scholar
• Sakthiswary R, Das S. The effects of TNF alpha antagonist therapy on bone metabolism in rheumatoid arthritis: a systematic review. Curr Drug Targets 2013;14(13):1552-7
   PubMed Web of Science ®Google Scholar
• Marotte H, Pallot-Prades B, Grange L, et al. A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab. Arthritis Res Ther 2007;9(3):R61
   PubMed Web of Science ®Google Scholar
• Wijbrandts CA, Klaasen R, Dijkgraaf MG, et al. Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss. Ann Rheum Dis 2009;68(3):373-6
   PubMed Web of Science ®Google Scholar
• Krieckaert CL, Nurmohamed MT, Wolbink G, Lems WF. Changes in bone mineral density during long-term treatment with adalimumab in patients with rheumatoid arthritis: a cohort study. Rheumatology (Oxford) 2013;52(3):547-53
   PubMed Web of Science ®Google Scholar
• Guler-Yuksel M, Allaart CF, Goekoop-Ruiterman YP, et al. Changes in hand and generalised bone mineral density in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis 2009;68(3):330-6
   PubMed Web of Science ®Google Scholar
• Chopin F, Garnero P, le Henanff A, et al. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Ann Rheum Dis 2008;67(3):353-7
   PubMed Web of Science ®Google Scholar
• Seriolo B, Paolino S, Sulli A, et al. Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis. Ann N Y Acad Sci 2006;1069:420-7
   PubMed Web of Science ®Google Scholar
• Kim SY, Schneeweiss S, Liu J, Solomon DH. Effects of disease-modifying antirheumatic drugs on nonvertebral fracture risk in rheumatoid arthritis: a population-based cohort study. J Bone Miner Res 2012;27(4):789-96
   PubMed Web of Science ®Google Scholar
• Wheater G, Hogan VE, Teng YK, et al. Suppression of bone turnover by B-cell depletion in patients with rheumatoid arthritis. Osteoporos Int 2011;22(12):3067-72
   PubMed Web of Science ®Google Scholar
• Garnero P, Thompson E, Woodworth T, Smolen JS. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. Arthritis Rheum 2010;62(1):33-43
   PubMed Web of Science ®Google Scholar
• Confavreux CB, Chapurlat RD. Systemic bone effects of biologic therapies in rheumatoid arthritis and ankylosing spondylitis. Osteoporos Int 2011;22(4):1023-36
   PubMed Web of Science ®Google Scholar
• Colucci S, Minielli V, Zambonin G, et al. Alendronate reduces adhesion of human osteoclast-like cells to bone and bone protein-coated surfaces. Calcif Tissue Int 1998;63(3):230-5
   PubMed Web of Science ®Google Scholar
• Wells George A, Cranney A, Peterson J, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008. Available from: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001155.pub2/abstract. [Last accessed April 2014]
   Google Scholar
• Wells George A, Cranney A, Peterson J, et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008. Available from: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004523.pub3/abstract. [Last accessed April 2014]
   Google Scholar
• Prieto-Alhambra D, Judge A, Arden NK, et al. Fracture prevention in patients with cognitive impairment presenting with a hip fracture: secondary analysis of data from the HORIZON Recurrent Fracture Trial. Osteoporos Int 2014;25(1):77-83
   PubMed Web of Science ®Google Scholar
• den Uyl D, Bultink IE, Lems WF. Advances in glucocorticoid-induced osteoporosis. Curr Rheumatol Rep 2011;13(3):233-40
   PubMed Web of Science ®Google Scholar
• Hakala M, Kroger H, Valleala H, et al. Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial. Scand J Rheumatol 2012;41(4):260-6
   PubMed Web of Science ®Google Scholar
• Benucci M, Saviola G, Baiardi P, et al. Effects of monthly intramuscular neridronate in rheumatic patients in chronic treatment with low-dose glucocorticoids. Clin Exp Rheumatol 2009;27(4):567-73
   PubMed Web of Science ®Google Scholar
• O’Ryan FS, Lo JC. Bisphosphonate-related osteonecrosis of the jaw in patients with oral bisphosphonate exposure: clinical course and outcomes. J Oral Maxillofac Surg 2012;70(8):1844-53
   PubMed Web of Science ®Google Scholar
• Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22(10):1479-91
   PubMed Web of Science ®Google Scholar
• Rasmusson L, Abtahi J. Bisphosphonate associated osteonecrosis of the jaw: an update on pathophysiology, risk factors, and treatment. Int J Dent 2014;2014:471035
   PubMedGoogle Scholar
• Khan AA, Sandor GK, Dore E, et al. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 2008;35(7):1391-7
   PubMed Web of Science ®Google Scholar
• Giusti A, Hamdy NA, Papapoulos SE. Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies. Bone 2010;47(2):169-80
   PubMed Web of Science ®Google Scholar
• Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the american society for bone and mineral research. J Bone Miner Res 2014;29(1):1-23
   PubMed Web of Science ®Google Scholar
• Schilcher J, Koeppen V, Aspenberg P, Michaelsson K. Risk of atypical femoral fracture during and after bisphosphonate use. N Engl J Med 2014;371(10):974-6
   PubMed Web of Science ®Google Scholar
• McNicholl DM, Heaney LG. The safety of bisphosphonate use in pre-menopausal women on corticosteroids. Curr Drug Saf 2010;5(2):182-7
   PubMedGoogle Scholar
• Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361(8):756-65
   PubMed Web of Science ®Google Scholar
• Cohen SB, Dore RK, Lane NE, et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008;58(5):1299-309
   PubMed Web of Science ®Google Scholar
• Bridgeman MB, Pathak R. Denosumab for the reduction of bone loss in postmenopausal osteoporosis: a review. Clin Ther 2011;33(11):1547-59
   PubMed Web of Science ®Google Scholar
• European public assessment report for Prolia. July 2014. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001120/human_med_001324.jsp&mid=WC0b01ac058001d124
   Google Scholar
• Jarrett SJ, Conaghan PG, Sloan VS, et al. Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis. Arthritis Rheum 2006;54(5):1410-14
   PubMed Web of Science ®Google Scholar
• Deodhar A, Dore RK, Mandel D, et al. Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 2010;62(4):569-74
   PubMed Web of Science ®Google Scholar
• Blake GM, Fogelman I. Theoretical model for the interpretation of BMD scans in patients stopping strontium ranelate treatment. J Bone Miner Res 2006;21(9):1417-24
   PubMed Web of Science ®Google Scholar
• Reginster JY. Cardiac concerns associated with strontium ranelate. Expert Opin Drug Saf 2014;13:1209-13
   PubMed Web of Science ®Google Scholar
• Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344(19):1434-41
   PubMed Web of Science ®Google Scholar
• Greenspan SL, Bone HG, Ettinger MP, et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 2007;146(5):326-39
   PubMed Web of Science ®Google Scholar
• Ebina K, Hashimoto J, Shi K, et al. Comparison of the effect of 18-month daily teriparatide administration on patients with rheumatoid arthritis and postmenopausal osteoporosis patients. Osteoporos Int 2014;25(12):2755-65
   PubMed Web of Science ®Google Scholar
• Saag KG, Zanchetta JR, Devogelaer JP, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 2009;60(11):3346-55
   PubMed Web of Science ®Google Scholar
• Migliore A, Massafra U, Bizzi E, et al. May etanercept and PTH (1-34) association heal erosions in early rheumatoid arthritis? A pilot study. Eur Rev Med Pharmacol Sci 2012;16(3):363-9
   PubMed Web of Science ®Google Scholar
• Satterwhite J, Heathman M, Miller PD, et al. Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis. Calcif Tissue Int 2010;87(6):485-92
   PubMed Web of Science ®Google Scholar
• McClung MRea. Odanacatib anti-fracture efficacy and safety in postmenopausal women with osteoporosis. Results from the phase III long-term odanacatib fracture trial (LOFT). American Society of Bone and Mineral Research symposium, USA, Houston; 2014
   Google Scholar
• McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 2014;370(5):412-20
   PubMed Web of Science ®Google Scholar
• Recker R, Benson C, Matsumoto T, et al. A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356(18):1809-22
   PubMed Web of Science ®Google Scholar
• de Nijs RN, Jacobs JW, Lems WF, et al. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med 2006;355(7):675-84
   PubMed Web of Science ®Google Scholar
• Meunier PJ, Roux C, Ortolani S, et al. Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis. Osteoporos Int 2009;20(10):1663-73
   PubMed Web of Science ®Google Scholar
• Reginster JY, Bruyere O, Sawicki A, et al. Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years. Bone 2009;45(6):1059-64
   PubMed Web of Science ®Google Scholar
• Kume K, Amano K, Yamada S, et al. The effect of tocilizumab on bone mineral density in patients with methotrexate-resistant active rheumatoid arthritis. Rheumatology (Oxford) 2014;53(5):900-3
   PubMed Web of Science ®Google Scholar